A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Niraparib
Sponsor: The Netherlands Cancer Institute
Collaborators: Tesaro, Inc.